Nan­cy Stagliano bags an­oth­er $45M for True North’s rare dis­ease R&D

Nan­cy Stagliano has a habit of re­main­ing pre­cise­ly on mes­sage when she talks about South San Fran­cis­co-based True North Ther­a­peu­tics.

Her new $45 mil­lion round an­nounced to­day brings the to­tal she’s raised for the biotech to $142 mil­lion. Yes, she says she still has some of that ear­li­er cash raised in the bank. But don’t look for her to tout how much run­way she has now, what kind of de­vel­op­ment time­lines are on the chalk board or say much about the prospect of an IPO af­ter a round that in­cludes in­vestors like Franklin Tem­ple­ton In­vest­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.